期刊文献+

2013-2015年医院下呼吸道标本铜绿假单胞菌检出率及耐药性分析 被引量:7

Detection rate and drug resistance of Pseudomonas aeruginosa in lower respiratory tract infection in hospital in 2013-2015
原文传递
导出
摘要 目的分析医院患者下呼吸道感染铜绿假单胞菌的临床分布及耐药性,为临床合理用药提供参考。方法收集2013-2015年医院门诊和住院患者下呼吸道标本,依据《全国临床检验操作规程》将标本接种于血平板和麦康凯平板上,置于35℃CO2孵箱中培养,采用API20NE鉴定系统确定菌种,药敏试验采用纸片扩散法(K-B),数据采用WHONET 5.3统计软件进行分析。结果 2013-2015年医院患者共分离病原菌9 847株,检出铜绿假单胞菌1 257株,检出率12.77%,3年检出率分别为9.50%、13.70%、15.20%,呈逐年上升趋势;其中住院部患者检出1 147株占91.25%,以呼吸科ICU、外科ICU和神经科为主,分别占25.46%、20.29%和14.40%,而门诊患者检出110株占8.75%;2013年铜绿假单胞菌对氨曲南、亚胺培南和哌拉西林的耐药率最高,分别为32.52%、30.67%和30.37%,2014年对头孢哌酮、氨曲南和哌拉西林的耐药率最高,分别为31.68%、29.95%和29.31%,2015年对头孢哌酮、氨曲南和亚胺培南的耐药率最高,分别为34.54%、29.41%和29.03%,对阿米卡星的耐药率3年内始终保持最低,分别为15.34%、14.36%和13.47%。结论 2013-2015年铜绿假单胞菌引起的下呼吸道感染呈逐年上升趋势,治疗时应充分考虑铜绿假单胞菌耐药性分布的变化和特点,减少碳青霉烯类抗菌药物使用,合理应用阿米卡星和头孢哌酮/舒巴坦。 OBJECTIVE To analyze the drug resistance and clinical distribution of Pseudomonas aeruginosain hospital caused lower respiratory tract infection,so as to provide reference for rational use of drugs in hospital.METHODS Samples in lower respiratory of patients in the department of outpatients and inpatients of hospital from Jan.2013 to Dec.2015 were collected,which were inoculated on blood plate and Macconkey tablet followed by National Clinical Laboratory Procedures and cultured in CO2 incubator under 35℃.API20 NF was used to identify bacteria,and K-B was used for drug sensitivity test.WHONET 5.3was used for data analysis.RESULTS A total of 9847 strains of P.aeruginosa were isolated in from the hospitalized patients 2013~2015,and 1 257 strains of P.aeruginosa were isolated,the isolation rate in each year was 9.50%,13.70%,15.20%,with an increasing trend year by year.A total of 1 147 strains were isolated from the patients in department of inpatients,accounting for91.25%,mainly in Department of Respiration ICU,Surgery ICU and Neurology,accounting for 25.46%,20.29%,and 14.40%,while 110 strains detected from the department of outpatients,accounting for 8.75%.In2013,the top 3drugs resistance rate of Pseudomonas aeruginosa were aztreonam,imipenem and piperacillin,accounting for 32.52%,30.67%and 30.37%respectively.In 2014,the top three were cefoperazone,aztreonam and piperacillin,accounting for 31.68%,29.95%and 29.31%respectively,and in 2015 cefoperazone,aztreonam and imipenem,accounting for 34.54%,29.41% and 29.03% respectively,while the resistance rate to amikacin kept the lowest in these three years which were 15.30%,14.30% and 13.50%respectively.CONCLUSIONThe hospital lower respiratory tract infection induced by P.aeruginosa has an increasing trend yearly from 2013 to 2015.The changes and characteristics of drug resistance of P.aeruginosashould be paid more attention in the treatment to reduce the use of antibiotics like carbapenem,and promote the rational use of amikacin and cefoperazone/sulbactam.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第19期4342-4344,共3页 Chinese Journal of Nosocomiology
基金 黑龙江科技厅研究基金资助项目(201207857)
关键词 铜绿假单胞菌 耐药性 呼吸道 抗菌药物 Pseudomonas aeruginosa Drug resistance Respiratory tract Antibiotics
  • 相关文献

参考文献13

  • 1王海兴,李建国,项辉,郭清莲.2092株铜绿假单胞菌医院感染的临床分布及耐药性分析[J].中华医院感染学杂志,2013,23(1):184-186. 被引量:47
  • 2谢强,马筱玲,卜素,周馨,周文静.铜绿假单胞菌临床分布及耐药性分析[J].中华医院感染学杂志,2013,23(5):1166-1168. 被引量:23
  • 3张鸿,申建维,孙秀琴,徐国鹏,吴汉明.医院感染铜绿假单胞菌的耐药性变迁分析[J].中华医院感染学杂志,2013,23(2):449-451. 被引量:21
  • 4Cavalcanti FL,Mirones CR,Paucar ER,et al.Mutational and acquired carbapenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from Recife,Brazil[J].Mem Inst Oswaldo Cruz,2015,110(8):1003-1009.
  • 5Saxena S,Banerjee G,Garg R,et al.Comparative study of biofilm formation in Pseudomonas aeruginosa isolates from patientsof lower respiratory tract infection[J].J Clin Diagn Res,2014,8(5):DC09-11.
  • 6Ahmed NH,Hussain T,Biswal I.Antimicrobial resistance of bacterial isolates from respiratory secretions of ventilated patients in a multi-specialty hospital[J].Avicenna J Med,2015,5(3):74-78.
  • 7Mahfoud M,Al Najjar M,Hamzeh AR.Multidrug resistance in Pseudomonas aeruginosaisolated from nosocomial respiratory and urinary infections in Aleppo,Syria[J].J Infect Dev Ctries,2015,9(2):210-213.
  • 8Saxena S,Banerjee G,Garg R,et al.CTX-M and PER-1group extended spectrumβ-lactamases-producing Pseudomonas aeruginosafrom the patients of lower respiratory tract infection[J].Indian J Med Microbiol,2015,33(1):191-192.
  • 9李静,刘磊,王俊平,陈玉龙,石明霞,张薇.肺部感染铜绿假单胞菌的临床特点[J].现代生物医学进展,2015,15(11):2119-2122. 被引量:6
  • 10Roemhild R,Barbosa C,Beardmore RE,et al.Temporal variation in antibiotic environments slows down resistance evolution inpathogenic Pseudomonas aeruginosa[J].Evol Appl,2015,8(10):945-955.

二级参考文献47

  • 1丛玉隆,金大鸣,王鸿利,冈田德弘,彭作辉,中国人群成人静脉血细胞分析参考范围调查协作组.中国人群成人静脉血细胞分析参考范围调查[J].中华医学杂志,2003,83(14):1201-1205. 被引量:176
  • 2陈文彬,潘祥林.诊断学[M].北京:人民卫生出版社,2006.
  • 3李家泰,李来云,王近.2000至2001年度中国细菌耐药研究.现代感染病进展杂志,2002,4:1-13.
  • 4Clinical and Laboratory Standards Institute(CLSI).Perform-ance standards for Antimicrobial susceptibility testing[S].M100-S17,CLSI,2007.
  • 5CLSI Performance standards for antimicrobial susceptibility testing[S]. Twenty second Informational supplement, M 100-$222012.32(3).
  • 6Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing Aminoglyeoside Therapy for Nosocornial Pneumonia Caused by Gram-Negative Bacteria [J]. Antimierob Agents Chemother, See comment in PubMed Commonsb, 1999, 43(3): 623-629.
  • 7Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of AmericaJAmerican Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults[J]. Clin Infect Dis, 2007, 44 (Suppl 2): $27-72.
  • 8Mohr JF, Jones A, Ostrosky-Zeichner L, et al. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonase aruginosa in a private, university-affiliated teaching hospital: an 8-year-experience 1995-2002 [J]. Antimicrob Agents, 2004, 24 (4): 346-351.
  • 9Park SY, Park HJ, Moon SM, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia[J]. BMC Infect Dis, 2012, 12(1): 308.
  • 10Robert A, Bonomo RA, Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa[J]. Clin Infect Dis, 2006, 43(Supp12): $49-56.

共引文献96

同被引文献76

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部